metformin has been researched along with lobeglitazone in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, JY; Jang, IJ; Kim, TE; Shin, D; Shin, SG; Yoon, SH; Yu, KS | 1 |
| Ahn, CW; Baik, SH; Cha, BS; Cho, YM; Jin, SM; Ku, BJ; Lee, KW; Lee, MK; Min, KW; Park, CY; Park, SW; Sung, YA; Yoon, KH | 1 |
| Cho, YM; Jin, HY; Kim, JH; Kim, SR; Lee, BW; Lee, YH; Rhee, EJ | 1 |
| Jeon, JY; Kim, MG; Kim, SY; Park, SJ | 1 |
| Davies, MJ; Kim, KM; Ku, EJ; Lee, JE; Lee, JH; Lee, SY; Lim, S | 1 |
| Cha, BS; Choi, DS; Choi, KM; Chun, SW; Kim, DM; Kim, KJ; Kim, MK; Kim, SG; Lee, HW; Lim, S; Mok, JO; Park, KS; Seo, JA; Shon, HS; Yoon, KH | 1 |
| Bae, JC; Han, JM; Kim, ES; Kim, IJ; Kim, MK; Kim, SS; Kim, YI; Koh, G; Kwon, MJ; Kwon, SK; Lee, CW; Nam-Goong, IS; Park, JH; Ryang, S; Yoo, S | 1 |
| Ahn, SH; Cho, Y; Choi, YJ; Hong, S; Kim, SH; Lee, E; Lee, YH; Seo, DH; Seo, S; Suh, YJ | 1 |
| Hong, JH; Lim, S; Moon, JS; Seong, K | 1 |
6 trial(s) available for metformin and lobeglitazone
| Article | Year |
|---|---|
Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.
Topics: Adult; Chromatography, Liquid; Cross-Over Studies; Drug Interactions; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; PPAR alpha; PPAR gamma; Pyrimidines; Republic of Korea; Tandem Mass Spectrometry; Thiazolidinediones | 2012 |
Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrimidines; Thiazolidinediones | 2015 |
Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Elasticity Imaging Techniques; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linear Models; Lipids; Liver; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Pyrimidines; Thiazolidinediones; Treatment Outcome | 2017 |
Pharmacokinetics of a Lobeglitazone/Metformin Fixed-Dose Combination Tablet (CKD-395 0.5/1000 mg) Versus Concomitant Administration of Single Agents and the Effect of Food on the Metabolism of CKD-395 in Healthy Male Subjects.
Topics: Adult; Area Under Curve; Cross-Over Studies; Drug Combinations; Fasting; Food-Drug Interactions; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Pyrimidines; Tablets; Thiazolidinediones; Young Adult | 2019 |
Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Pyrimidines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome | 2020 |
A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Double-Blind Method; Drug Therapy, Combination; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Protease Inhibitors; Pyrimidines; Thiazolidinediones; Treatment Outcome | 2022 |
3 other study(ies) available for metformin and lobeglitazone
| Article | Year |
|---|---|
Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study.
Topics: Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Resistance; Male; Metformin; Middle Aged; Prognosis; Pyrimidines; Republic of Korea; Sitagliptin Phosphate; Thiazolidinediones | 2020 |
Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrimidines; Republic of Korea; Thiazolidinediones; Treatment Outcome | 2022 |
Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: Third agent study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2023 |